Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,005 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study.
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Morimoto K, et al. Among authors: yamaguchi h. Oncoimmunology. 2021 Jul 8;10(1):1950411. doi: 10.1080/2162402X.2021.1950411. eCollection 2021. Oncoimmunology. 2021. PMID: 34290909 Free PMC article.
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer.
Morimoto K, Yamada T, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Morimoto K, et al. Among authors: yamaguchi h. Lung Cancer. 2021 Nov;161:26-33. doi: 10.1016/j.lungcan.2021.08.015. Epub 2021 Aug 31. Lung Cancer. 2021. PMID: 34500218
Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study.
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Morimoto K, et al. Among authors: yamaguchi h. J Cancer Res Clin Oncol. 2022 Sep;148(9):2437-2446. doi: 10.1007/s00432-021-03782-5. Epub 2021 Sep 12. J Cancer Res Clin Oncol. 2022. PMID: 34510271
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. Taniguchi H, et al. Among authors: yamaguchi h. Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0. Nat Commun. 2019. PMID: 30651547 Free PMC article.
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
Wakuda K, Yamaguchi H, Kenmotsu H, Fukuda M, Takeshita M, Suetsugu T, Kirita K, Ebi N, Hataji O, Miura S, Chibana K, Okamoto I, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K. Wakuda K, et al. Among authors: yamaguchi h. BMC Cancer. 2020 May 1;20(1):370. doi: 10.1186/s12885-020-06874-6. BMC Cancer. 2020. PMID: 32357848 Free PMC article.
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S. Taniguchi H, et al. Among authors: yamaguchi h. Cancer Sci. 2017 Jan;108(1):53-60. doi: 10.1111/cas.13111. Epub 2016 Dec 30. Cancer Sci. 2017. PMID: 27783866 Free PMC article.
Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Tsuchiya-Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I. Tsuchiya-Kawano Y, et al. Among authors: yamaguchi h. Oncologist. 2020 Jun;25(6):475-e891. doi: 10.1634/theoncologist.2019-0746. Epub 2019 Oct 24. Oncologist. 2020. PMID: 31649134 Free PMC article. Clinical Trial.
Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer.
Takemoto S, Nakamura Y, Fukuda M, Senju H, Gyotoku H, Taniguchi H, Shimada M, Ikeda T, Yamaguchi H, Nakatomi K, Hayashi N, Soda H, Mukae H. Takemoto S, et al. Among authors: yamaguchi h. Thorac Cancer. 2017 Nov;8(6):577-581. doi: 10.1111/1759-7714.12483. Epub 2017 Aug 3. Thorac Cancer. 2017. PMID: 28771961 Free PMC article. Clinical Trial.
Presence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case series.
Ogawara D, Soda H, Tomono H, Iwasaki K, Hara T, Jinnai S, Funayama T, Okuno D, Taniguchi H, Yoshida M, Harada T, Umemura A, Fukuda Y, Yamaguchi H, Mukae H. Ogawara D, et al. Among authors: yamaguchi h. Thorac Cancer. 2018 Oct;9(10):1305-1311. doi: 10.1111/1759-7714.12844. Epub 2018 Aug 20. Thorac Cancer. 2018. PMID: 30126069 Free PMC article.
5,005 results